MY147864A - Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin - Google Patents

Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin

Info

Publication number
MY147864A
MY147864A MYPI20061656A MYPI20061656A MY147864A MY 147864 A MY147864 A MY 147864A MY PI20061656 A MYPI20061656 A MY PI20061656A MY PI20061656 A MYPI20061656 A MY PI20061656A MY 147864 A MY147864 A MY 147864A
Authority
MY
Malaysia
Prior art keywords
beta
skin
connective tissue
tissue diseases
adrenoceptor agonists
Prior art date
Application number
MYPI20061656A
Other languages
English (en)
Inventor
Morten Sloth Weidner
Original Assignee
Astion Dev As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Dev As filed Critical Astion Dev As
Publication of MY147864A publication Critical patent/MY147864A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI20061656A 2005-04-13 2006-04-12 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin MY147864A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500529 2005-04-13

Publications (1)

Publication Number Publication Date
MY147864A true MY147864A (en) 2013-01-31

Family

ID=36703472

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20061656A MY147864A (en) 2005-04-13 2006-04-12 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin

Country Status (28)

Country Link
US (4) US8426475B2 (enExample)
EP (1) EP1719507B1 (enExample)
JP (1) JP5021621B2 (enExample)
KR (1) KR101355422B1 (enExample)
CN (1) CN101203214B (enExample)
AR (1) AR054249A1 (enExample)
AT (1) ATE473735T1 (enExample)
AU (1) AU2006233502B2 (enExample)
BR (1) BRPI0609361A2 (enExample)
CA (1) CA2604758C (enExample)
CY (1) CY1111541T1 (enExample)
DE (1) DE602006015387D1 (enExample)
DK (1) DK1719507T3 (enExample)
EA (1) EA016082B1 (enExample)
ES (1) ES2348920T3 (enExample)
HR (1) HRP20100552T1 (enExample)
IL (1) IL186491A (enExample)
MX (1) MX2007012794A (enExample)
MY (1) MY147864A (enExample)
NO (1) NO331211B1 (enExample)
NZ (1) NZ562940A (enExample)
PL (1) PL1719507T3 (enExample)
PT (1) PT1719507E (enExample)
RS (1) RS51464B (enExample)
SI (1) SI1719507T1 (enExample)
TW (1) TWI366457B (enExample)
WO (1) WO2006108424A2 (enExample)
ZA (1) ZA200708748B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0604826D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders and pain
MX2009000382A (es) 2006-07-10 2009-01-27 Intervet Int Bv Composiciones de enantiomero zilpaterol y metodos para elaborar y usar tales composiciones.
GB0624757D0 (en) * 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
GB0805535D0 (en) 2008-03-27 2008-04-30 Univ Leicester Scar prevention
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
CN102267917B (zh) * 2011-06-15 2013-07-31 浙江工业大学 一种盐酸甲氧那明的合成方法
UA115445C2 (uk) * 2012-05-18 2017-11-10 Інтервет Інтернешнл Б.В. Спосіб збільшення приросту бройлерних курей
GB2513297A (en) * 2013-03-08 2014-10-29 Univ Leicester Methods
CN104606177B (zh) * 2014-11-21 2018-02-02 苏州君宁新药开发中心有限公司 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用
WO2018000098A1 (en) * 2016-06-30 2018-01-04 Cipher Pharmaceuticals Inc. Treatment of inflammatory myopathies
CN106580978A (zh) * 2016-11-30 2017-04-26 郑州仁宏医药科技有限公司 一种治疗皮炎的西药组合物及其应用
US10576043B2 (en) * 2017-08-10 2020-03-03 Avro Life Sciences, Inc. Transdermal drug delivery system
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
US10947196B2 (en) * 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
US11607395B2 (en) 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
CN112300237A (zh) * 2020-04-13 2021-02-02 苏州恩泰新材料科技有限公司 海豹胆酸的制备方法及其应用
BR112023005697A2 (pt) * 2020-10-09 2023-04-25 Mc2 Therapeutics Ltd Tratamento de condições dermatológicas
US20240043499A1 (en) 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production
CN116236467B (zh) * 2023-02-07 2023-10-27 中国人民解放军总医院 西马特罗或其衍生物的新用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7464B (en) 1973-01-16 1974-11-27 J Voorhees Treatment of proliferating skin diseases with papavine alkaloids
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
SU895445A1 (ru) * 1980-05-15 1982-01-07 Военно-Медицинская Краснознаменная Академия Им. С.М.Кирова Способ лечени кожных форм красной волчанки
US4574129A (en) 1984-01-31 1986-03-04 Bristol-Myers Company Topical nonsteroidal anti-inflammatory methods
JPS61154201A (ja) 1984-12-26 1986-07-12 Matsushita Electric Ind Co Ltd 誘電体フイルタ
US4699777A (en) 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
PH25150A (en) 1986-06-05 1991-03-13 Ciba Geigy Ag Novel pharmaceutical preparation for topical application
US4980159A (en) 1989-05-23 1990-12-25 Bristol-Myers Squibb Company Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects
RU2092105C1 (ru) * 1989-11-20 1997-10-10 Нижегородский научно-исследовательский кожно-венерологический институт Способ определения терапевтической тактики у больных очаговой склеродермией и дискоидной красной волчанкой
DE4014252A1 (de) * 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer
US5919827A (en) 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
ES2084825T3 (es) 1990-07-26 1996-05-16 Monsanto Co Procedimiento de preparacion de poliamidas entrecruzadas.
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
JP3294876B2 (ja) 1992-07-20 2002-06-24 トキコ株式会社 給油装置
WO1995019336A1 (de) 1994-01-12 1995-07-20 Iovis Biomedical And Pharmaceutical Consultants Phenylethanolaminether und ihre verwendung als beta-adrenorezeptor-agonisten
JPH07304647A (ja) 1994-05-09 1995-11-21 Kao Corp マッサージ用組成物
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
GB9510162D0 (en) * 1995-05-19 1995-07-12 Bouras Elias Compositions for the treatment of skin conditions
JPH09110674A (ja) 1995-10-16 1997-04-28 Kao Corp 浴用剤組成物
FR2740040B1 (fr) 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
EP0979081A4 (en) * 1997-04-30 2003-05-02 Bridge Pharma Inc COMPOSITION AND METHODS USING EUTOMER
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002040021A2 (en) 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
HUP0402577A3 (en) 2001-12-03 2011-05-30 Wyeth Corp Indole derivatives as inhibitors of cytosolic phospholipase a2, process for producing them and pharmaceutical compositions containing them
CN1646143A (zh) * 2002-04-19 2005-07-27 艾升发展公司 β－2肾上腺素受体兴奋剂与氨基糖的结合及其在治疗免疫功能紊乱方面的应用
AU2003228133A1 (en) 2002-04-22 2003-11-03 Umc Utrecht Holding B.V. Reduction of unwanted immune reactions
WO2003092617A2 (en) 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US20040229849A1 (en) 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
EP1553955A4 (en) * 2002-09-24 2008-11-05 Combinatorx Inc METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PRO-INFLAMMATORY CYTOKINES
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
TW200902047A (en) * 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040209850A1 (en) * 2003-04-15 2004-10-21 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
EP1646370A1 (en) 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
TW200522932A (en) 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
JP2007512337A (ja) * 2003-11-21 2007-05-17 コンビナトアールエックス インコーポレーティッド 炎症性障害の治療のための方法および試薬
WO2005089741A2 (en) 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
WO2005102296A2 (en) 2004-04-23 2005-11-03 Heptagen Limited Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
EP1786410A2 (en) * 2004-09-07 2007-05-23 Sosei R&D Ltd. The treatment of inflammatory disorders and pain

Also Published As

Publication number Publication date
KR101355422B1 (ko) 2014-02-06
US20130237607A1 (en) 2013-09-12
WO2006108424A3 (en) 2006-12-14
NZ562940A (en) 2010-02-26
CY1111541T1 (el) 2015-08-05
ATE473735T1 (de) 2010-07-15
CN101203214B (zh) 2012-11-21
MX2007012794A (es) 2008-02-22
KR20080005957A (ko) 2008-01-15
US20060235048A1 (en) 2006-10-19
PL1719507T3 (pl) 2010-12-31
HRP20100552T1 (hr) 2010-11-30
NO331211B1 (no) 2011-10-31
US20190125699A1 (en) 2019-05-02
EA016082B1 (ru) 2012-02-28
IL186491A0 (en) 2008-08-07
SI1719507T1 (sl) 2010-11-30
US8426475B2 (en) 2013-04-23
CA2604758C (en) 2014-11-25
TWI366457B (en) 2012-06-21
EA200702204A1 (ru) 2008-04-28
JP2008535873A (ja) 2008-09-04
NO20075527L (no) 2008-01-14
US9907765B2 (en) 2018-03-06
ES2348920T3 (es) 2010-12-17
AU2006233502A1 (en) 2006-10-19
WO2006108424A9 (en) 2007-08-09
HK1091739A1 (en) 2007-01-26
AU2006233502B2 (en) 2011-07-28
PT1719507E (pt) 2010-10-21
BRPI0609361A2 (pt) 2010-03-30
CA2604758A1 (en) 2006-10-19
EP1719507B1 (en) 2010-07-14
RS51464B (sr) 2011-04-30
AR054249A1 (es) 2007-06-13
JP5021621B2 (ja) 2012-09-12
DK1719507T3 (da) 2010-11-01
US20170157068A1 (en) 2017-06-08
ZA200708748B (en) 2010-03-31
DE602006015387D1 (de) 2010-08-26
IL186491A (en) 2011-12-29
WO2006108424A2 (en) 2006-10-19
TW200719882A (en) 2007-06-01
CN101203214A (zh) 2008-06-18
EP1719507A1 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
MX2007012794A (es) Composiciones para el tratamiento de trastornos del tejido conectivo de la piel.
IL201479A (en) Use of tapentadol for the preparation of pain medication
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
MX2010004074A (es) Combinacion 059.
WO2009124266A3 (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
BR112012006010A2 (pt) composto de glicina
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
PL2081910T3 (pl) Nowe związki
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
MX2009011900A (es) Curacion de herida diabetica.
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
GB2456475A (en) Composition for the treatment of skin conditions
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
TW200510352A (en) Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
PL2165704T3 (pl) Zastosowanie alweryny w leczeniu dolegliwości skórnych
MX2009011819A (es) Formulaciones de aminoacido n-halogenado.
WO2022043273A3 (en) Oral care composition comprising a fructanase
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.